Related Experiment Videos
Enoximone pharmacokinetics in infants.
P D Booker1, S Gibbons, J I Stewart
1University of Liverpool, UK.
British Journal of Anaesthesia
|September 19, 2000
Summary
Enoximone pharmacokinetics in infants are similar to adults, but hepatic or renal dysfunction requires reduced infusion rates. This study analyzed drug concentrations in 20 infants post-cardiopulmonary bypass.
Area of Science:
- Pediatric Pharmacology
- Clinical Pharmacokinetics
- Neonatal Intensive Care
Background:
- Enoximone is used in infants post-cardiopulmonary bypass.
- Understanding enoximone pharmacokinetics in infants is crucial for safe and effective dosing.
Purpose of the Study:
- To determine enoximone and enoximone sulphoxide pharmacokinetics in infants.
- To assess the impact of hepatic and renal dysfunction on enoximone elimination.
Main Methods:
- Plasma concentrations of enoximone and its metabolite were measured in 20 infants.
- Pharmacokinetic analysis was performed using TOPFIT software.
- Patients received a continuous infusion of enoximone post-cardiopulmonary bypass.
Main Results:
- Enoximone clearance was lower and half-life longer in infants with hepatic dysfunction.
- Enoximone sulphoxide elimination half-life was prolonged in infants with renal dysfunction.
- Infant enoximone pharmacokinetics were comparable to adult data.
Conclusions:
- Enoximone dosing in infants requires adjustment in cases of hepatic or renal impairment.
- Continuous infusion parameters should be modified based on infant's organ function.
- Further research may refine dosing guidelines for specific infant populations.